Investor FAQ
Answers to frequently asked questions about Cardiol Therapeutics Inc. (TSX:CRDL).
Latest News?
Not disclosed in available filings.
Clinical Trials
CardiolRx™, the lead drug candidate of Cardiol Therapeutics, is in clinical development for heart disease, specifically targeting recurrent pericarditis and acute myocarditis. The FDA has granted Orphan Drug Designation for CardiolRx™ for these conditions, and two Phase II studies are planned following successful Phase I trials that demonstrated safety and tolerability.